A carregar...
EGFR/ErbB2-Targeting Lapatinib Therapy for Aggressive Prolactinomas
CONTEXT: Approximately 10% to 20% of prolactinomas are resistant to dopamine agonist therapy. The ErbB signaling pathway may drive aggressive prolactinoma behavior. OBJECTIVE: We evaluated lapatinib, an ErbB1-epidermal growth factor receptor (EGFR)/ErbB2 or human EGFR2 (HER2) tyrosine kinase inhibit...
Na minha lista:
| Publicado no: | J Clin Endocrinol Metab |
|---|---|
| Main Authors: | , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Oxford University Press
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7823257/ https://ncbi.nlm.nih.gov/pubmed/33150390 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/clinem/dgaa805 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|